GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dicerna Pharmaceuticals Inc (NAS:DRNA) » Definitions » Cyclically Adjusted PS Ratio

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Cyclically Adjusted PS Ratio : (As of May. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Dicerna Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Dicerna Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Dicerna Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dicerna Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Dicerna Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dicerna Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dicerna Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Dicerna Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dicerna Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dicerna Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dicerna Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Dicerna Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Dicerna Pharmaceuticals's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec20 is calculated as:

For example, Dicerna Pharmaceuticals's adjusted Revenue per Share data for the fiscal year that ended in Dec20 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec20 (Change)*Current CPI (Dec20)
=2.215/109.8968*109.8968
=2.215

Current CPI (Dec20) = 109.8968.

Dicerna Pharmaceuticals Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201112 1.779 95.213 2.053
201212 1.579 96.871 1.791
201312 0.000 98.326 0.000
201412 0.000 99.070 0.000
201512 0.009 99.792 0.010
201612 0.000 101.863 0.000
201712 0.047 104.011 0.050
201812 0.111 105.998 0.115
201912 0.349 108.420 0.354
202012 2.215 109.897 2.215

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dicerna Pharmaceuticals  (NAS:DRNA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Dicerna Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Dicerna Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Hayden Avenue, Lexington, MA, USA, 02421
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, cardiovascular diseases, cancers, and other liver problems. The company uses its ribonucleic acid interference technology platform to develop its products. In addition, Dicerna's proprietary GalXC technology focuses on silencing disease-causing genes. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others. Dicerna generates revenue by forming collaborative relationships with pharmaceutical companies such as Eli Lilly, Roche, Novo Nordisk, and others.
Executives
Bob D Brown officer: See Remarks 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Shreeram Aradhye officer: EVP & Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Marc D Kozin director
Douglas Fambrough director, officer: President and CEO C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
James B Weissman officer: Chief Operating Officer & EVP C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Regina M. Paglia officer: Chief Human Resources Officer C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421
Robert D. Ciappenelli officer: Chief Commercial Officer DICERNA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140
Adam Koppel director C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Stephen K Doberstein director 129 ELSIE STREET, SAN FRANCISCO CA 94110
Patrick M. Gray director C/O CIVITAS SOLUTIONS, INC. 313 CONGRESS STREET, 6TH FLOOR BOSTON MA 02210
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Martin I Freed director 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Stephen J Hoffman director C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301

Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Headlines

From GuruFocus

Dicerna to Participate in 16th Annual Citi Biopharma Conference

By Business Wire Business Wire 09-02-2021